# Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

> **NCT04339218** · PHASE3 · RECRUITING · sponsor: **Institut Bergonié** · enrollment: 214 (estimated)

## Conditions studied

- Lung Adenocarcinoma
- Cryotherapy Effect

## Interventions

- **DEVICE:** Cryoablation
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04339218
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-28
- **Primary completion:** 2026-08-27
- **Final completion:** 2028-08-27
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339218, "Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04339218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*